Indeed, a greater understanding of how tumor stroma and TME comprehensively affect immunotherapy will provide important advances: CAF markers correlate with T cell immunosuppression, blocking the effects of both CD8+ T cells and NK cells, especially through the release of various chemokines and cytokines (mainly IL-6 production), leading to poor clinical outcome. The gene discussed is CD8A; the disease is neoplasm.